Treatment for Lymphoplasmacytic Lymphoma Receives Orphan Designation

The FDA granted orphan drug designation to CLR 131, a phospholipid-drug conjugate that selectively delivers the radioisotope iodine-131 to tumor cells.

CLR 131 is being evaluated in the ongoing phase II CLOVER-1 trial, which is investigating the agent’s safety and efficacy in patients with relapsed or refractory B-cell lymphomas, including lymphoplasmacytic lymphoma, a rare form of non-Hodgkin lymphoma.

The drug has previously received orphan designation for the treatment of multiple myeloma, as well as fast-track designation for the treatment of relapsed or refractory diffuse large B-cell lymphoma.

Source: Cellectar Biosciences press release, January 6, 2020.